Copyright
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Jan 7, 2022; 10(1): 128-135
Published online Jan 7, 2022. doi: 10.12998/wjcc.v10.i1.128
Published online Jan 7, 2022. doi: 10.12998/wjcc.v10.i1.128
Increased levels of lactate dehydrogenase and hypertension are associated with severe illness of COVID-19
Zhen-Mu Jin, Mo Zheng, Department of Rheumatology, Immunology and Allergy, Wenzhou Central Hospital, The Second Affiliated Hospital of Shanghai University, Affiliated Dingli Clinical Institute of Wenzhou Medical University, Wenzhou 325000, Zhejiang Province, China
Ji-Chan Shi, Yue-Ying Zhou, Fang Cheng, Jing Cai, Xian-Gao Jiang, Department of Infectious Diseases, Wenzhou Central Hospital, The Second Affiliated Hospital of Shanghai University, Affiliated Dingli Clinical Institute of Wenzhou Medical University, Wenzhou 325000, Zhejiang Province, China
Que-Lu Chen, Department of Radiology, Wenzhou Central Hospital, The Second Affiliated Hospital of Shanghai University, Affiliated Dingli Clinical Institute of Wenzhou Medical University, Wenzhou 325000, Zhejiang Province, China
Author contributions: Jiang XG and Jin ZM designed the study; Jin ZM, Shi JC, Zheng M, and Chen QL performed the study and collected the data; Zhou YY, Chen F, and Cai J analyzed the data; Jin ZM drafted the manuscript; and all authors have read and approved the final manuscript.
Supported by the Wenzhou Major Technology Innovation Project , No. ZY202004 .
Institutional review board statement: Approval was obtained from the Ethics Committee of Wenzhou Central Hospital (approval number: L2020-01-037).
Informed consent statement: Informed consent was waived by the Ethics Committee of Wenzhou Central Hospital due to the retrospective nature of this study.
Conflict-of-interest statement: The authors declare no conflict of interest for this article.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Xian-Gao Jiang, MD, Professor, Department of Infectious Diseases, Wenzhou Central Hospital, The Second Affiliated Hospital of Shanghai University, Affiliated Dingli Clinical Institute of Wenzhou Medical University, No. 252 Bailidong Road, Wenzhou 325000, Zhejiang Province, China. xiangao368@163.com
Received: June 30, 2021
Peer-review started: June 30, 2021
First decision: July 16, 2021
Revised: July 26, 2021
Accepted: November 17, 2021
Article in press: November 17, 2021
Published online: January 7, 2022
Processing time: 183 Days and 0.3 Hours
Peer-review started: June 30, 2021
First decision: July 16, 2021
Revised: July 26, 2021
Accepted: November 17, 2021
Article in press: November 17, 2021
Published online: January 7, 2022
Processing time: 183 Days and 0.3 Hours
Core Tip
Core Tip: Coronavirus disease 2019 (COVID-19) is amid an ongoing pandemic. It has been shown that patients with cardiovascular comorbidities are at higher risk of severe illness of COVID-19. Although most COVID-19 patients have mild symptoms and generally good outcomes, some of them still show severe illness. Patients with hypertension and elevated levels of lactate dehydrogenase may be at high risk of severe illness of COVID-19.